The company will use the money to continue development of its flagship Immunoscore colon cancer assay, among other things.
Companies are now expected to have their tests cleared by authorities for clinical use, and to bring their entire catalogs into line with the new regulations by May 2022.
The partners will jointly develop and commercialize gene expression assays to predict response to cancer immunotherapy, based on the nCounter platform.
The firm, HalioDx, was formed following the departure of Qiagen Marseille's executive team and all its employees.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.